Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Amortization of Deferred Charges (2023)

Historic Amortization of Deferred Charges for Contineum Therapeutics (CTNM) over the last 1 years, with Q4 2023 value amounting to -$1000.0.

  • Contineum Therapeutics' Amortization of Deferred Charges changed N/A to -$1000.0 in Q4 2023 from the same period last year, while for Sep 2024 it was -$1000.0, marking a year-over-year change of. This contributed to the annual value of -$198000.0 for FY2023, which is N/A changed from last year.
  • Latest data reveals that Contineum Therapeutics reported Amortization of Deferred Charges of -$1000.0 as of Q4 2023.
  • In the past 5 years, Contineum Therapeutics' Amortization of Deferred Charges ranged from a high of $26000.0 in Q1 2023 and a low of -$223000.0 during Q2 2023